No annual revenue total was found in MUSTANG BIO, INC.'s SEC filings.
Mustang Bio, Inc. (MBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-3.53M
-51.1% vs year-ago TTM
Operating cash flow (TTM)
$-4.57M
+17.6% vs year-ago TTM
Free cash flow
$-11.41M
+77.0% vs prior year
EPS (TTM)
$-0.53
+19.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
70.92M
+80.0% vs prior year
Net cash
$17.27M
FY 2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680048
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$2.4M | -$16.2M | -$49.3M | -$76.2M | -$66.7M |
| Net income | -$1.9M | -$15.8M | -$51.6M | -$77.5M | -$66.4M |
| Diluted EPS | -$0.39 | -$38.57 | -$299.95 | -$10.09 | — |
| Operating cash flow | -$5.3M | -$11.4M | -$49.5M | -$65.1M | -$53.7M |
| Free cash flow | — | -$11.4M | -$49.5M | -$67.8M | -$57.7M |
| Total assets | $17.6M | $9.3M | $17.7M | $92.4M | $125.2M |
| Total liabilities | $8.1M | $13.2M | $17.6M | $46.1M | $12.8M |
| Stockholders' equity | $9.5M | -$3.9M | $123,000 | $46.3M | $112.4M |
| Cash and investments | $17.3M | $6.8M | $6.2M | $75.7M | $109.6M |
| Total debt | $0 | $900,000 | $2.5M | $3.9M | $2.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Listing notice
|
Apr 17, 2026 | Apr 15, 2026 |
| 10-K | Annual report | Mar 19, 2026 | Dec 31, 2025 |
All 405 Mustang Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.